瑞舒伐他汀联合替格瑞洛对急性冠脉综合征患者PCI术后血脂水平及MACE发生率的影响

Rosuvastatin Combined with Ticagrelor on Blood Lipid Level and MACE Occurrence Rate of Patients with Acute Coronary Syndromes after PCI

目的:研究瑞舒伐他汀联合替格瑞洛在急性冠脉综合征(ACS)患者经皮冠脉介入术(PCI)术后的应用效果。方法:选取2016年1月~2017年5月某院ACS患者122例,依照治疗方案不同分为观察组和对照组各61例,两组均行PCI治疗,术后常规服用阿司匹林治疗,在此基础上对照组采用替格瑞洛治疗,观察组采用瑞舒伐他汀+替格瑞洛治疗。比较两组术前及术后3个月血脂指标[高密度脂蛋白胆固醇(HDL-C)、三酰甘油(TG)、总胆固醇(TC)]变化,术后随访1年,统计两组主要不良心血管事件(MACE)发生率。结果:术后3个月观察组HDL-C高于对照组,TG、TC低于对照组(P<0.05);术后随访1年,均无病例脱落,观察组MACE发生率(9.84%)低于对照组26.23%(P<0.05)。结论:ACS患者PCI术后采用瑞舒伐他汀联合替格瑞洛治疗,能有效控制其血脂水平,降低MACE发生率。

Objective： To explore the effect of rosuvastatin combined with ticagrelor on blood lipid level and MACE occurrence rate of patients with acute coronary syndromes after PCI. Methods：122 patients with ACS in a hospital from January 2016 to May 2017 were selected and randomly divided into two groups, 61 ca ses in each group. Both groups were treated with PCI and aspirin by taking orally after treatment. On this basis, the control group was treated with tigravilol, and the observation group was treated with resuvastatin tigravilol. Changes of blood lipid parameters （high density lipoprotein cholesterol, HDI. C, triacylglycer ol, TG and total cholesterol, TC） before and after treatment three month were compared in the two groups. After 1 year of follow up, the incidence of major adverse cardiovascular events （MACE） was calculated. Re- sults： Three month after treatment, the observation group had higher HDL C and lower TG, TC compared with the control （P〈0.05）. During one year postoperative follow up, none case was away, and the MACE rate in observation group was 9.84%, significant lower than that in control group （26.23） （P〈0.05）. Conclusion： Rosuvastatin combined with ticagrelor can effectively control its blood lipid level and reduce the inci dence of MACE for patients with ACS.